Chemicals

Samsung, LG and South Korea’s trade secrets dilemma

The long read: Few countries are more focused on the threat of IP leaks to China than South Korea. But when it comes to shoring up legal protections for trade secrets, senior leaders have put on the brakes, anticipating threats to key industry players and national technology goals

Samsung, LG and South Korea’s trade secrets dilemma
Dialog’s patents will boost Renesas’ fast growing licensing business
19 Feb 2021

Dialog’s patents will boost Renesas’ fast growing licensing business

The purchase of the UK chipmaker will contribute to the monetisation programme’s potential, particularly within circuit technologies

Seven top IP tips for biotech SMEs
18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions

Latest

View all
15 Feb 2021

Uptrend in oppositions could spell costly delays for Indian patent applicants

Practitioners say greater attention to detail during the prosecution process can head off frivolous challenges Read more

12 Feb 2021

Ford CEO weighs in on “really embarrassing” South Korean battery trade secrets fight

With the auto giant set for a high-profile roll out of several new electric vehicles, the dispute between LG Chem and SK Innovation is once again in the spotlight Read more

11 Feb 2021

How the rise of PTAB discretionary denials impacts Hatch-Waxman strategies

The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics Read more

4 Feb 2021

SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs

Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary Read more

News

View all
15 Dec 2020

East Asian giants leave their stamp on the IP market

IAM reveals the Asia IP Elite members for 2020 from two dynamic high-tech jurisdictions: South Korea and Taiwan Read more

14 Dec 2020

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

14 Sep 2020

Changes to Ukraine’s IP laws have major implications for the life sciences

Two recent pieces of legislation have brought the country’s patent system more closely in line with EU rules Read more

Analysis

View all
3 Feb 2021

Japanese chemical giants score patent litigation wins in China

Two of country’s top industrials got successful results in the market that constitutes their number one business challenge Read more

1 Feb 2021

“It’s really embarrassing” - LG and SK feel the political heat ahead of US trade secrets decision

South Korean PM’s comments show that IP enforcement does not happen in a vacuum Read more

14 Jan 2021

New Brazilian biotech patent examination guidelines a “missed opportunity”

While boosting transparency, the many difficulties faced by life sciences innovators when applying for protection in the country are not addressed Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more